Dallas- and Austin-based venture capital investor Sevin Rosen Funds has re-upped on a developer of molecular diagnostics services and technology. Reserach Triangle Park, North Carolina-based Metabolon, which is developing molecular diagnostics for detecting and measuring the aggression and stage of diseases such as diabetes and cancer, has raised $13M in a Series D Convertible Preferred Stock Round. The round was led by Keating Cpaital, and also included Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners. Sevin Rosen is an existing investor in Metabolon. More information »